Sedana Medical AB (OSTO:SEDANA) advances towards US market entry amid mixed sales performance and financial adjustments.

Sedana Medical AB (OSTO:SEDANA) reports a positive EBITDA and stable gross margin amidst sales challenges, while advancing its US market entry.

Sedana Medical AB (OSTO:SEDANA) achieves record sales growth and makes significant strides in US market entry, despite challenges in European markets.

Sedana Medical (OM:SEDANA) remains unprofitable, posting losses that have increased at 1% per year over the past five years. Looking ahead, the company is forecast to stay in the red for at least the next three years. Revenue is projected to grow by 26.45% per year, outpacing the broader Swedish market’s 3.9% expected annual growth. Investors are weighing this robust revenue outlook against the risk backdrop of continued losses and an uncertain path to profitability. See our full analysis for...

Sedana Medical AB (FRA:7D2A) reports positive EBITDA and strategic progress despite facing seasonal and market-specific hurdles.